Cargando…

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains

BACKGROUND: In a range of human disorders such as multiple myeloma (MM), immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can lead to pathological aggregation and deposition of IgLCs in different tissues, which in turn leads to severe and potentially fatal organ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sternke-Hoffmann, Rebecca, Pauly, Thomas, Norrild, Rasmus K., Hansen, Jan, Tucholski, Florian, Høie, Magnus Haraldson, Marcatili, Paolo, Dupré, Mathieu, Duchateau, Magalie, Rey, Martial, Malosse, Christian, Metzger, Sabine, Boquoi, Amelie, Platten, Florian, Egelhaaf, Stefan U., Chamot-Rooke, Julia, Fenk, Roland, Nagel-Steger, Luitgard, Haas, Rainer, Buell, Alexander K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898917/
https://www.ncbi.nlm.nih.gov/pubmed/36737754
http://dx.doi.org/10.1186/s12915-022-01506-w
_version_ 1784882532707205120
author Sternke-Hoffmann, Rebecca
Pauly, Thomas
Norrild, Rasmus K.
Hansen, Jan
Tucholski, Florian
Høie, Magnus Haraldson
Marcatili, Paolo
Dupré, Mathieu
Duchateau, Magalie
Rey, Martial
Malosse, Christian
Metzger, Sabine
Boquoi, Amelie
Platten, Florian
Egelhaaf, Stefan U.
Chamot-Rooke, Julia
Fenk, Roland
Nagel-Steger, Luitgard
Haas, Rainer
Buell, Alexander K.
author_facet Sternke-Hoffmann, Rebecca
Pauly, Thomas
Norrild, Rasmus K.
Hansen, Jan
Tucholski, Florian
Høie, Magnus Haraldson
Marcatili, Paolo
Dupré, Mathieu
Duchateau, Magalie
Rey, Martial
Malosse, Christian
Metzger, Sabine
Boquoi, Amelie
Platten, Florian
Egelhaaf, Stefan U.
Chamot-Rooke, Julia
Fenk, Roland
Nagel-Steger, Luitgard
Haas, Rainer
Buell, Alexander K.
author_sort Sternke-Hoffmann, Rebecca
collection PubMed
description BACKGROUND: In a range of human disorders such as multiple myeloma (MM), immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can lead to pathological aggregation and deposition of IgLCs in different tissues, which in turn leads to severe and potentially fatal organ damage. However, IgLCs can also be highly soluble and non-toxic. It is generally thought that the cause for this differential solubility behaviour is solely found within the IgLC amino acid sequences, and a variety of individual sequence-related biophysical properties (e.g. thermal stability, dimerisation) have been proposed in different studies as major determinants of the aggregation in vivo. Here, we investigate biophysical properties underlying IgLC amyloidogenicity. RESULTS: We introduce a novel and systematic workflow, Thermodynamic and Aggregation Fingerprinting (ThAgg-Fip), for detailed biophysical characterisation, and apply it to nine different MM patient-derived IgLCs. Our set of pathogenic IgLCs spans the entire range of values in those parameters previously proposed to define in vivo amyloidogenicity; however, none actually forms amyloid in patients. Even more surprisingly, we were able to show that all our IgLCs are able to form amyloid fibrils readily in vitro under the influence of proteolytic cleavage by co-purified cathepsins. CONCLUSIONS: We show that (I) in vivo aggregation behaviour is unlikely to be mechanistically linked to any single biophysical or biochemical parameter and (II) amyloidogenic potential is widespread in IgLC sequences and is not confined to those sequences that form amyloid fibrils in patients. Our findings suggest that protein sequence, environmental conditions and presence and action of proteases all determine the ability of light chains to form amyloid fibrils in patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-022-01506-w.
format Online
Article
Text
id pubmed-9898917
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98989172023-02-05 Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains Sternke-Hoffmann, Rebecca Pauly, Thomas Norrild, Rasmus K. Hansen, Jan Tucholski, Florian Høie, Magnus Haraldson Marcatili, Paolo Dupré, Mathieu Duchateau, Magalie Rey, Martial Malosse, Christian Metzger, Sabine Boquoi, Amelie Platten, Florian Egelhaaf, Stefan U. Chamot-Rooke, Julia Fenk, Roland Nagel-Steger, Luitgard Haas, Rainer Buell, Alexander K. BMC Biol Research Article BACKGROUND: In a range of human disorders such as multiple myeloma (MM), immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can lead to pathological aggregation and deposition of IgLCs in different tissues, which in turn leads to severe and potentially fatal organ damage. However, IgLCs can also be highly soluble and non-toxic. It is generally thought that the cause for this differential solubility behaviour is solely found within the IgLC amino acid sequences, and a variety of individual sequence-related biophysical properties (e.g. thermal stability, dimerisation) have been proposed in different studies as major determinants of the aggregation in vivo. Here, we investigate biophysical properties underlying IgLC amyloidogenicity. RESULTS: We introduce a novel and systematic workflow, Thermodynamic and Aggregation Fingerprinting (ThAgg-Fip), for detailed biophysical characterisation, and apply it to nine different MM patient-derived IgLCs. Our set of pathogenic IgLCs spans the entire range of values in those parameters previously proposed to define in vivo amyloidogenicity; however, none actually forms amyloid in patients. Even more surprisingly, we were able to show that all our IgLCs are able to form amyloid fibrils readily in vitro under the influence of proteolytic cleavage by co-purified cathepsins. CONCLUSIONS: We show that (I) in vivo aggregation behaviour is unlikely to be mechanistically linked to any single biophysical or biochemical parameter and (II) amyloidogenic potential is widespread in IgLC sequences and is not confined to those sequences that form amyloid fibrils in patients. Our findings suggest that protein sequence, environmental conditions and presence and action of proteases all determine the ability of light chains to form amyloid fibrils in patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12915-022-01506-w. BioMed Central 2023-02-03 /pmc/articles/PMC9898917/ /pubmed/36737754 http://dx.doi.org/10.1186/s12915-022-01506-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sternke-Hoffmann, Rebecca
Pauly, Thomas
Norrild, Rasmus K.
Hansen, Jan
Tucholski, Florian
Høie, Magnus Haraldson
Marcatili, Paolo
Dupré, Mathieu
Duchateau, Magalie
Rey, Martial
Malosse, Christian
Metzger, Sabine
Boquoi, Amelie
Platten, Florian
Egelhaaf, Stefan U.
Chamot-Rooke, Julia
Fenk, Roland
Nagel-Steger, Luitgard
Haas, Rainer
Buell, Alexander K.
Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title_full Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title_fullStr Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title_full_unstemmed Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title_short Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
title_sort widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898917/
https://www.ncbi.nlm.nih.gov/pubmed/36737754
http://dx.doi.org/10.1186/s12915-022-01506-w
work_keys_str_mv AT sternkehoffmannrebecca widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT paulythomas widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT norrildrasmusk widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT hansenjan widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT tucholskiflorian widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT høiemagnusharaldson widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT marcatilipaolo widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT dupremathieu widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT duchateaumagalie widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT reymartial widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT malossechristian widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT metzgersabine widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT boquoiamelie widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT plattenflorian widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT egelhaafstefanu widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT chamotrookejulia widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT fenkroland widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT nagelstegerluitgard widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT haasrainer widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains
AT buellalexanderk widespreadamyloidogenicitypotentialofmultiplemyelomapatientderivedimmunoglobulinlightchains